New directions in cancer therapy

Helix BioPharma Corporation is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. Helix is currently listed on TSX and FSE under the symbol “HBP”

home_image

DOS47

Our most innovative technological platform for the treatment of solid tumors

News

March 3, 2016

Helix BioPharma Corp. Reports on Advancement of its Lung Cancer Drug Candidate L-DOS47

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the Trial Steering Committee has completed a review of safety data and recommended the opening of patient screening for the sixteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).

February 4, 2016

Changes in the Leadership of Helix Polska

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces changes in the leadership team of its Polish subsidiary “Helix Polska”. The appointments are effective as of January, 28, 2016.

January 29, 2016

Helix BioPharma Corp Announces Appointment of New Directors to the Board of Directors

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, has today announced the appointment of Mr. Albert Beraldo and Mr. George J. Anders to the board of directors. The appointments are effective as of January 28, 2016. At the same time, Mr. Gary Littlejohn and Mr. Yvon Bastien submitted their resignations to the board of directors for its consideration.

January 21, 2016

Helix BioPharma Corp Initiates Enrollment In The Second Dosing Cohort Of U.S. Combination Treatment Study Of Its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the second dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin (“LDOS001”).

January 12, 2016

Helix BioPharma Corp Announces Appointment of Permanent New CEO and Changes at Board Level

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” or the “Company” and listed on TSX & FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that it has appointed Dr. Zbigniew Markowski as Chief Executive Officer, replacing Mr. Gary Littlejohn who was serving as Interim CEO.

January 6, 2016

Helix BioPharma Corp Signs License Agreement with Helix Polska to Develop Cancer Therapies in Poland

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” and listed on TSX & FSE: “HBP”) (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has granted a world-wide exclusive license for v-DOS47, an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2), to its wholly-owned subsidiary, Helix Polska.

December 16, 2015

Helix BioPharma Corp. Announces The Results of Its Annual General Meeting

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General Meeting (the “Meeting”) was held today as scheduled. 

December 11, 2015

Helix BioPharma Corp. Announces First Quarter 2016 Results

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2016, ended October 31, 2015

November 4, 2015

Helix BioPharma Corp. Initiates Enrollment for Fourteenth Cohort in Polish Phase I/II Clinical Study of Its L-DOS47 Lung Cancer Drug

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of cancer, today announced the
opening of patient screening for the fourteenth dose level cohort in the Company’s ongoing Phase I/II
clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).

October 29, 2015

2015 Annual Report

October 29, 2015

Helix BioPharma Corp. Annouces Fiscal 2015 Results

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug
candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July
31, 2015 and the appointment of Gary Littlejohn as Interim Chief Executive Officer as of November 1, 2015.

September 30, 2015

Helix BioPharma Corp. Announces Appointment of A New Director and Leadership Transition Plans

Aurora, Ontario – September 30, 2015 – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Mr. Gary Littlejohn has been appointed as a director of Helix, effective as of September 23, 2015. To help facilitate a smooth leadership transition while Helix searches for a new permanent President and Chief Executive Officer, he has been appointed as a Consultant to Helix effective as of September 29, 2015. As previously disclosed, Mr. Robert Verhagen will continue to act as Helix’s President and Chief Executive Officer until November 1, 2015.

September 23, 2015

Helix BioPharma Corp. Announces Director Resignation

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Stacy L. Wills has voluntarily resigned from Helix’s board of directors, effective as of September 25, 2015.

September 18, 2015

Helix BioPharma Corp. Announces Leadership Transition

Aurora, Ontario – September 18, 2015 – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Robert Verhagen has resigned as President and Chief Executive Officer (CEO), effective as of November 1, 2015, and as a member of the Board of Directors, effective immediately. Mr. Verhagen will continue to serve as CEO to assist in the Company’s management transition and he has been with Helix since 2012. In the event that the Board has not appointed a new Chief Executive Officer by November 1, 2015, Helix’s Board of Directors intends to appoint Yvon Bastien, Chairman of the Board, to assume the role of President and Chief Executive Officer on an interim basis.

September 8, 2015

Helix BioPharma Corp. Gives Presentation And Update of L‐DOS47 Clinical Study At World Conference On Lung Cancer

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, yesterday presented an update of the ongoing clinical study LDOS002 for their drug candidate L‐DOS47 during the 16th World Conference on Lung Cancer held in Denver Colorado.

September 7, 2015

16th World Conference On Lung Cancer 2015

L-DOS47 Polish Phase 1 Study Update

August 24, 2015

Helix BioPharma Corp. Announces Upcoming Presentation Of L‐DOS47 At World Conference on Lung Cancer

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that an abstract for its lead lung cancer candidate L‐DOS47 has been selected for oral presentation at the 16 World Conference on Lung Cancer (WCLC) held in Denver Colorado, September 6‐9,2015.

June 22, 2015

Helix BioPharma Corp. Initiate Enrollment For Thirteen Cohort on Polish I/II Clinical Study of Its Lung Cancer Drug L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the thirteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).

June 15, 2015

Helix BioPharma Corp. Announces Q3 Fiscal 2015 Results

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the third quarter of fiscal 2015, ended April 30, 2015.